Clinical trial
A Phase 2, Single Arm, Open Label Extension Study, Evaluating the Long-Term Safety and Clinical Efficacy of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
NCT05897424 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Single Arm, Open Label Extension Study, Evaluating the Long-Term Safety and Clinical Efficacy of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
- Lead sponsor
- Sanofi
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- June 20, 2024
- Completion date
- September 30, 2028
- Enrollment
- 185 (estimated)
- Sites
- 40
Conditions
As the registry lists them; a condition with its own page is linked.